Try our Advanced Search for more refined results

FDA Says Celgene's Revlimid Tied To Higher Cancer Risks

By Megan Stride (May 8, 2012, 3:54 PM EDT) -- The U.S. Food and Drug Administration said Monday that some newly diagnosed patients who received Celgene Corp.'s blood cancer treatment drug Revlimid are at an increased risk of developing certain new types of cancers....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Companies

Government Agencies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!